Profarma is expanding its innovative product portfolio with the launch of a project aimed at developing advanced pharmaceutical forms and technologies for treating cystic fibrosis. Supported by funding from the European Union, this initiative marks a significant step forward in enhancing treatment options for cystic fibrosis patients worldwide.
New Pharmaceutical Forms of Ivacaftor:
As part of this project, Profarma will create and develop new pharmaceutical forms of ivacaftor, a crucial medication for cystic fibrosis patients. The new forms include:
- Ivacaftor tablets
- Ivacaftor granules for pediatric use
- Ivacaftor extended-release tablets
These innovative ivacaftor products are designed to improve the accessibility and quality of cystic fibrosis treatment, benefiting patients in both regulated markets and developing countries.
Project Highlights:
- Project Value: €1,476,686.24
- Funding from the European Regional Development Fund: €833,867.07
- Project Duration: December 2023 – May 2026
“We are excited to embark on this new project, which highlights our commitment to innovation and improving patient outcomes,” said Kaushalesh Vaishnav, Product Development Manager at Profarma. “With the support of the European Union, we aim to develop pharmaceutical forms that will significantly enhance the treatment options available to cystic fibrosis patients, particularly in underserved regions.”
The development of these new ivacaftor forms will involve cutting-edge research and technology, ensuring that the products meet the highest standards of quality and efficacy.
For more information about Profarma’s new project and its impact on cystic fibrosis treatment, please contact us directly.
Contact:
info@profarma.lt
